Nitrofurantoin Lyrus Life Sciences (Nitrofurantoin)

Nitrofurantoin is reduced inside bacterial cells by flavoprotein enzymes to highly reactive intermediates. These metabolites damage bacterial DNA, ribosomal proteins and other macromolecules, disrupting carbohydrate metabolism and leading to rapid bactericidal activity against susceptible urinary pathogens.

The dosage of Nitrofurantoin Lyrus Life Sciences is determined by the prescribing clinician based on the patient’s age, renal function and the severity of infection. Typical adult regimens range from 50 mg to 100 mg taken two to four times daily, but the exact schedule must be set by a qualified health professional.

Nitrofurantoin is generally avoided in the later stages of pregnancy (after 36 weeks) because of the risk of neonatal hemolysis. In early pregnancy, it may be used when the benefits outweigh potential risks. Limited data are available for breastfeeding; caution is advised and the prescriber should evaluate the risk‑benefit profile.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

The most common alternative for uncomplicated UTIs is trimethoprim‑sulfamethoxazole. Nitrofurantoin has a narrower spectrum focused on urinary pathogens and achieves high urinary concentrations, which can be advantageous in resistant infections. Trimethoprim‑sulfamethoxazole offers broader systemic coverage but may encounter higher rates of resistance and has different safety considerations, such as sulfa‑related hypersensitivity.

Store the product at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets in a dry place and out of reach of children. Do not refrigerate or freeze the product, as this could affect its stability.

Nitrofurantoin Lyrus Life Sciences is taken orally with a full glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal upset. The tablets should be swallowed whole; they should not be crushed, chewed, or dissolved unless specifically instructed by a healthcare professional.

Serious adverse events include pulmonary toxicity (interstitial lung disease or acute respiratory distress), hepatic injury, hemolytic anemia in patients with G6PD deficiency, severe allergic reactions such as anaphylaxis, and peripheral neuropathy. Patients should be instructed to seek immediate medical attention if they experience persistent cough, shortness of breath, jaundice, dark urine, rash, or numbness.

Nitrofurantoin should be avoided in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to nitrofurantoin or other nitrofurans, G6PD deficiency, and in late pregnancy (after 36 weeks gestation). Caution is also advised for individuals with a history of pulmonary disease or hepatic dysfunction.